Neuronetics

Neuronetics ROA

The Return on Assets (ROA) of Neuronetics (STIM) as of Oct 9, 2026 is -27.55 %. In the previous year, Return on Assets (ROA) was -31.02 % — a change of -11.18% (higher).

ROA

-27.55 %

YoY

-11.18%

Last updated:

In 2025, Neuronetics's return on assets (ROA) was -27.55 %, a -11.18% increase from the -31.02 % ROA in the previous year.

The Neuronetics ROA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROA
Date
ROA
Jan 1, 2018
-20.59 USD
Jan 1, 2019
-29.00 USD
Jan 1, 2020
-34.90 USD
Jan 1, 2021
-22.09 USD
Jan 1, 2022
-31.79 USD
Jan 1, 2023
-26.06 USD
Jan 1, 2024
-31.02 USD
Jan 1, 2025
-27.55 USD
The Neuronetics ROA history
YEARROAYoY
-27.55 %-11.18%
-31.02 %+19.02%
-26.06 %-18.02%
-31.79 %+43.93%
-22.09 %-36.72%
-34.90 %+20.37%
-29.00 %+40.81%
-20.59 %-50.07%
-41.24 %-8.96%
-45.30 %—
Access this data via the Eulerpool API

Neuronetics Stock analysis

What does Neuronetics do? Neuronetics Inc is a globally leading company in the field of non-invasive neuromodulatory technology. It was founded in 2003 and is headquartered in Malvern, Pennsylvania. The company specializes in the development and production of transcranial magnetic stimulation devices that can be used in the treatment of psychiatric disorders, particularly severe depression. Neuronetics' business model is based on selling its patented technology, called NeuroStar Advanced Therapy, to medical facilities worldwide. The company works closely with leading psychiatrists and clinical neurophysiologists to ensure that their devices meet the highest quality standards and can provide the best possible help to patients. The company has achieved a number of significant milestones in recent years. For example, in 2008, it received the first FDA approval for its technology. Since then, Neuronetics has continuously developed and improved its technology and has also obtained approvals in Europe and other parts of the world. Neuronetics is divided into various divisions, including research and development, manufacturing, and sales. Each of these departments is focused on ensuring the highest quality standards and ensuring that the technology of NeuroStar Advanced Therapy meets the needs of patients and medical personnel. The technology of NeuroStar Advanced Therapy is based on transcranial magnetic stimulation (TMS), which uses gentle magnetic fields to stimulate the activity of certain brain regions. The stimulation can help restore the balance of neurotransmitters in the brain and thus alleviate depression. Treatment with NeuroStar Advanced Therapy has significant advantages over conventional antidepressant medications. In many cases, it leads to faster improvement of symptoms and does not cause any of the undesirable side effects that can occur with medication. Overall, Neuronetics has developed a revolutionary technology with NeuroStar Advanced Therapy that can help millions of people around the world overcome their depression. The company is proud to contribute to improving the quality of life for people and will continue to develop innovative solutions in the field of neuromodulatory technology in the future. Neuronetics is one of the most popular companies on Eulerpool.

ROA Details

Understanding Neuronetics's Return on Assets (ROA)

Neuronetics's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Neuronetics's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Neuronetics's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Neuronetics’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Neuronetics stock

Return on Assets (ROA) of Neuronetics is -27.55 % in 2025.

Return on Assets (ROA) of Neuronetics changed from -31.02 % to -27.55 %, representing a -11.18% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Assets (ROA) Neuronetics since 2006 – with annual values, charts, and detailed analysis.

Return on Assets, also known as ROA, is a financial metric used to measure a company's profitability. It is used to determine how effectively a company uses its assets to generate profits. It is also referred to as the ratio of net income to total assets. ROA is an important indicator of a company's overall financial performance as it measures the company's ability to generate more profit from the assets it employs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Assets (ROA)'s Neuronetics with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Assets (ROA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Assets (ROA).

Access this data via the Eulerpool API

Profitability — Neuronetics

All Key Metrics — Neuronetics